Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
J Gynecol Oncol. 2023 Jul;34(4):e42. doi: 10.3802/jgo.2023.34.e42. Epub 2023 Feb 3.
To compare survival outcomes, posttreatment complications, and quality of life (QoL) of early-stage cervical cancer patients with intermediate-risk factors between those who received adjuvant pelvic radiation and those without adjuvant treatment.
Stages IB-IIA cervical cancer patients classified as having intermediate-risk following primary radical surgery were included. After propensity score weighted adjustment, all baseline demographic and pathological characteristics of 108 women who received adjuvant radiation and 111 women who had no adjuvant treatment were compared. The primary outcomes were progression-free survival (PFS) and overall survival (OS). The secondary outcomes included treatment-related complications and QoL.
Median follow-up time was 76.1 months in the adjuvant radiation group and 95.4 months in the observation group. The 5-year PFS (91.6% in the adjuvant radiation group and 88.4% in the observation group, p=0.42) and OS (90.1% in the adjuvant radiation group and 93.5% in the observation group, p=0.36) were not significantly different between the groups. There was no significant association between adjuvant treatment and overall recurrence/death in the Cox proportional hazard model. However, a substantial reduction in pelvic recurrence was observed in participants with adjuvant radiation (hazard ratio=0.15; 95% confidence interval=0.03-0.71). Grade 3/4 treatment-related morbidities and QoL scores were not significantly different between the groups.
Adjuvant radiation was associated with a lower risk of pelvic recurrence. However, its significant benefit in reducing overall recurrence and improving survival in early-stage cervical cancer patients with intermediate-risk factors could not be demonstrated.
比较接受辅助盆腔放疗与未接受辅助治疗的中危因素早期宫颈癌患者的生存结局、治疗后并发症和生活质量(QoL)。
纳入经根治性手术治疗后具有中危因素的ⅠB-ⅡA 期宫颈癌患者。在进行倾向评分加权调整后,比较 108 例接受辅助放疗和 111 例未接受辅助治疗的患者的所有基线人口统计学和病理特征。主要结局为无进展生存期(PFS)和总生存期(OS)。次要结局包括治疗相关并发症和 QoL。
辅助放疗组的中位随访时间为 76.1 个月,观察组为 95.4 个月。辅助放疗组 5 年 PFS(91.6%)和 OS(90.1%)与观察组(88.4%和 93.5%)相比无显著差异(p=0.42 和 p=0.36)。在 Cox 比例风险模型中,辅助治疗与总复发/死亡之间无显著相关性。然而,在接受辅助放疗的患者中,盆腔复发的风险显著降低(风险比=0.15;95%置信区间=0.03-0.71)。两组间 3/4 级治疗相关不良事件和 QoL 评分无显著差异。
辅助放疗与较低的盆腔复发风险相关,但在中危因素的早期宫颈癌患者中,不能证明其在降低总体复发和改善生存方面具有显著益处。